Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: Lack of association with clinical phenotypes

Abstract

Objectives. Dystrobrevin binding protein 1 (Dysbindin) is a plausible candidate gene for major depressive disorders (MDD) due to its involvement in synaptic signaling, plasticity and localization in the brain. Methods. Two intronic SNPs of DTNBP1; rs760761 (P1320) and rs2619522 (P1763) were analyzed in 206 patients with DSM-IV MDD to investigate the functional impact of genotypes on susceptibility for depression and some clinical phenotypes. The Sequenom iPLEX assay (Sequenom, Cambridge, MA) was used for genotyping. Results and Conclusions. Despite the limited power of analysis, our results showed that these two SNPs in DTNPB1 gene were not related to clinical phenotypes such as melancholia, age at onset, suicidality and co-morbid anxiety disorders, as well as to treatment response phenotypes.

Key words::

• DTNBP1 (dystrobrevin binding protein 1)
• major depressive disorder (MDD)
• clinical phenotypes
• treatment response
• SNP

Acknowledgments

We are grateful to all study participants. This study was supported by a grant from the Belgian National Fund for Scientific Research (FNRS; 3.4.530.07 F) and from an unrestricted grant from Lundbeck A/S to the Group for the Study of the Resistant Depression (GSRD).

Statement of interest

Dr Kasper has received grant/research support from Eli Lilly, Lundbeck, Bristol-Myers Squibb, Glaxo-SmithKline, Organon, Sepracor and Servier; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Organon, Schwabe, Sepracor, Servier, Janssen, and Novartis; and has served on speakers’ bureaus for AstraZeneca, Eli Lily, Lundbeck, Schwabe, Sepracor, Servier, Pierre Fabre, and Janssen. Dr Lecrubier has received honoraria from Pierre Fabre, Lundbeck, Servier, and Pfizer and is a member of the speakers/advisory boards of Eli Lilly, Sanofi, and Novartis. Professor Montgomery has or has been consultant/speaker for: AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Merz, Neurim, Pierre Fabre, Pfizer, Sanofi, Servier, Shire, Sepracor, Takeda, Targacept, Wyeth. Professor Zohar has received grant/research support from Lundbeck, Servier and Pfizer, has served as a consultant or on advisory boards for Servier, Pfizer, Solvay and Actelion, and has served on speakers’ bureaus for Lundbeck, GSK, Jazz and Solvay. Professor Mendlewicz (Board of Servier and Lundbeck Neuroscience Institute), Drs Kocabas, Linotte, Massat, Noro, Oswald, Souery (participation to national advisory boards: Astra Zeneca, BMS, Janssen Cilag, Eli Lilly) report no financial or other relationship relevant to the subject of this article.